Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.53 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.53 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.49 |
| ▸ | FDPS | P14324 | 5/20 | 0.48 |
| ▸ | LAP3 | P28838 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17887101 | 0.84 | LPAR3 (0.60) | LPAR3LPAR2LPAR1 | |
| SCHEMBL7804490 | 0.83 | CYP3A4 (0.50) | LPAR3LPAR2LPAR1FDPSCYP3A4 | |
| SCHEMBL7804495 | 0.81 | CYP3A4 (0.48) | LPAR3LPAR2LPAR1SMPD1FDPS | |
| SCHEMBL23001237 | 0.81 | LPAR3 (0.56) | LPAR3LPAR2LPAR1SMPD1FDPS | |
| SCHEMBL23001236 | 0.81 | LPAR3 (0.56) | LPAR3LPAR2LPAR1SMPD1FDPS | |
| SCHEMBL22129546 | 0.79 | FDPS (0.47) | LPAR3LPAR2LPAR1SMPD1FDPS | |
| SCHEMBL17887099 | 0.79 | LPAR3 (0.64) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL18708275 | 0.79 | LPAR3 (0.64) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL29194068 | 0.79 | LPAR3 (0.64) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL2776462 | 0.79 | CYP3A4 (0.58) | LPAR3LPAR2LPAR1SMPD1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010025116-A1 | Aluminum salts of phosphinic acids | TICONA GMBH | 2001-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025116-A1 | Aluminum salts of phosphinic acids | PPA1, PHOSPHO1, AGPS | LPAR3 1176/4885LPAR2 709/4885LPAR1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.